|
Submission ALP-POS-42f3de95
|
|
0
|
137
|
March 9, 2021
|
|
Submission DAV-ILL-89eb723b
|
|
7
|
254
|
March 8, 2021
|
|
Submission DAV-ILL-edda7d6f
|
|
0
|
154
|
March 8, 2021
|
|
Jorgensen et al MPro inhibitors
|
|
1
|
718
|
March 8, 2021
|
|
Submission MAT-POS-5369c344
|
|
0
|
107
|
March 7, 2021
|
|
Submission JIN-POS-6dc588a4
|
|
0
|
125
|
March 7, 2021
|
|
Submission ALP-POS-95f71980
|
|
0
|
103
|
March 7, 2021
|
|
Submission MAT-POS-932d1078
|
|
0
|
103
|
March 7, 2021
|
|
Submission LUK-UNK-e7d6e252
|
|
0
|
123
|
March 6, 2021
|
|
Submission LUK-THE-533040b5
|
|
0
|
101
|
March 6, 2021
|
|
Submission ALP-POS-6d96567b
|
|
0
|
130
|
March 6, 2021
|
|
Submission ALP-POS-a0a4abd7
|
|
0
|
148
|
March 6, 2021
|
|
Submission ALP-POS-e4f7337d
|
|
0
|
122
|
March 2, 2021
|
|
Submission ALP-UNI-8d415491
|
|
0
|
97
|
March 2, 2021
|
|
Submission EDJ-MED-cf4b0d25
|
|
0
|
157
|
March 2, 2021
|
|
Submission LUK-UNK-17c446f9
|
|
0
|
125
|
March 2, 2021
|
|
Submission ALP-UNI-c3ef0aba
|
|
0
|
138
|
March 1, 2021
|
|
Submission LUK-UNK-02ef1050
|
|
0
|
133
|
March 1, 2021
|
|
Submission LUK-UNK-3fbaf2c5
|
|
0
|
142
|
March 1, 2021
|
|
Submission MIC-UNK-0a05c952
|
|
0
|
157
|
February 28, 2021
|
|
Submission MAT-POS-dd3ad2b5
|
|
0
|
160
|
February 28, 2021
|
|
Submission MAT-POS-90505e2b
|
|
0
|
110
|
February 28, 2021
|
|
Submission NIR-THE-5be8b355
|
|
5
|
221
|
February 28, 2021
|
|
Submission EDJ-MED-946e547c
|
|
3
|
292
|
February 26, 2021
|
|
Submission EDJ-MED-611d11e7
|
|
0
|
147
|
February 25, 2021
|
|
Submission RAL-THA-e002e396
|
|
0
|
121
|
February 24, 2021
|
|
Submission VLA-UNK-792b5d03
|
|
0
|
136
|
February 24, 2021
|
|
Submission EDJ-MED-15e90dfc
|
|
0
|
121
|
February 24, 2021
|
|
Submission EDJ-MED-6d9ff7d0
|
|
0
|
106
|
February 24, 2021
|
|
Submission DAR-DIA-b4e9dd8d
|
|
0
|
109
|
February 23, 2021
|